47 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
1 May 23
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
9:05am
studies with simufilam, including anticipated patient enrollment goals in 2023 for our Phase 3 studies; the safety or efficacy of simufilam in patients
8-K
EX-99.1
524 e3f2tl
14 Jun 21
Cassava Sciences Announces the Appointment of
4:14pm
8-K
EX-99.1
leccm vh3wd15v
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-99.1
go9 b3iu0bq
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-10.1
fix50bho5jw6kx
11 May 18
Departure of Directors or Certain Officers
5:29pm
8-K
iqpgo
18 Nov 14
Departure of Directors or Certain Officers
12:00am